Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Purpose

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.

Conditions

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage IA Breast Cancer AJCC v8
  • Anatomic Stage IB Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage IIA Breast Cancer AJCC v8
  • Anatomic Stage IIB Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Anatomic Stage IIIB Breast Cancer AJCC v8
  • Anatomic Stage IIIC Breast Cancer AJCC v8
  • Central Nervous System Neoplasm
  • Clinical Stage I Cutaneous Melanoma AJCC v8
  • Clinical Stage IA Cutaneous Melanoma AJCC v8
  • Clinical Stage IB Cutaneous Melanoma AJCC v8
  • Clinical Stage II Cutaneous Melanoma AJCC v8
  • Clinical Stage IIA Cutaneous Melanoma AJCC v8
  • Clinical Stage IIB Cutaneous Melanoma AJCC v8
  • Clinical Stage IIC Cutaneous Melanoma AJCC v8
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Hodgkin Lymphoma
  • Malignant Bone Neoplasm
  • Malignant Brain Neoplasm
  • Malignant Solid Neoplasm
  • Malignant Testicular Neoplasm
  • Non-Hodgkin Lymphoma
  • Pathologic Stage I Cutaneous Melanoma AJCC v8
  • Pathologic Stage IA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IB Cutaneous Melanoma AJCC v8
  • Pathologic Stage II Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage III Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • Prognostic Stage I Breast Cancer AJCC v8
  • Prognostic Stage IA Breast Cancer AJCC v8
  • Prognostic Stage IB Breast Cancer AJCC v8
  • Prognostic Stage II Breast Cancer AJCC v8
  • Prognostic Stage IIA Breast Cancer AJCC v8
  • Prognostic Stage IIB Breast Cancer AJCC v8
  • Prognostic Stage III Breast Cancer AJCC v8
  • Prognostic Stage IIIA Breast Cancer AJCC v8
  • Prognostic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IIIC Breast Cancer AJCC v8
  • Stage I Cervical Cancer AJCC v8
  • Stage I Colorectal Cancer AJCC v8
  • Stage I Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage I Ovarian Cancer AJCC v8
  • Stage I Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage I Uterine Corpus Cancer AJCC v8
  • Stage IA Cervical Cancer AJCC v8
  • Stage IA Ovarian Cancer AJCC v8
  • Stage IA Uterine Corpus Cancer AJCC v8
  • Stage IA1 Cervical Cancer AJCC v8
  • Stage IA2 Cervical Cancer AJCC v8
  • Stage IB Cervical Cancer AJCC v8
  • Stage IB Ovarian Cancer AJCC v8
  • Stage IB Uterine Corpus Cancer AJCC v8
  • Stage IB1 Cervical Cancer AJCC v8
  • Stage IB2 Cervical Cancer AJCC v8
  • Stage IC Ovarian Cancer AJCC v8
  • Stage II Cervical Cancer AJCC v8
  • Stage II Colorectal Cancer AJCC v8
  • Stage II Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage II Ovarian Cancer AJCC v8
  • Stage II Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage II Uterine Corpus Cancer AJCC v8
  • Stage IIA Cervical Cancer AJCC v8
  • Stage IIA Colorectal Cancer AJCC v8
  • Stage IIA Ovarian Cancer AJCC v8
  • Stage IIA1 Cervical Cancer AJCC v8
  • Stage IIA2 Cervical Cancer AJCC v8
  • Stage IIB Cervical Cancer AJCC v8
  • Stage IIB Colorectal Cancer AJCC v8
  • Stage IIB Ovarian Cancer AJCC v8
  • Stage IIC Colorectal Cancer AJCC v8
  • Stage III Cervical Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage III Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Stage III Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage III Uterine Corpus Cancer AJCC v8
  • Stage IIIA Cervical Cancer AJCC v8
  • Stage IIIA Colorectal Cancer AJCC v8
  • Stage IIIA Ovarian Cancer AJCC v8
  • Stage IIIA Uterine Corpus Cancer AJCC v8
  • Stage IIIA1 Ovarian Cancer AJCC v8
  • Stage IIIA2 Ovarian Cancer AJCC v8
  • Stage IIIB Cervical Cancer AJCC v8
  • Stage IIIB Colorectal Cancer AJCC v8
  • Stage IIIB Ovarian Cancer AJCC v8
  • Stage IIIB Uterine Corpus Cancer AJCC v8
  • Stage IIIC Colorectal Cancer AJCC v8
  • Stage IIIC Ovarian Cancer AJCC v8
  • Stage IIIC Uterine Corpus Cancer AJCC v8
  • Stage IIIC1 Uterine Corpus Cancer AJCC v8
  • Stage IIIC2 Uterine Corpus Cancer AJCC v8

Eligibility

Eligible Ages
Between 18 Years and 39 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosed and/or treated with cancer between ages 18-39 at USC hospitals. - Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician. - Must be within three months of a de novo cancer diagnosis at recruitment and on/indicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study. - Patients must have anticipated survival of >1-year at time of diagnosis.

Exclusion Criteria

  • Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician. - Primary language other than English or Spanish. - Inability to complete a survey and/or wear an accelerometer either per the patient or in consultation with the clinician's judgment.

Study Design

Phase
Study Type
Observational
Observational Model
Case-Only
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Observational (actigraph, surveys) Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.
  • Other: Medical Device Usage and Evaluation
    Wear an actigraph GT3X-BT accelerometer
  • Other: Quality-of-Life Assessment
    Complete survey
    Other names:
    • Quality of Life Assessment
  • Other: Survey Administration
    Complete survey

Recruiting Locations

Los Angeles General Medical Center
Los Angeles, California 90033
Contact:
Kimberly Miller
323-865-0674
Kim.Miller@med.usc.edu

USC / Norris Comprehensive Cancer Center
Los Angeles, California 90033
Contact:
Kimberly Miller
323-865-0674
Kim.Miller@med.usc.edu

More Details

Status
Recruiting
Sponsor
University of Southern California

Study Contact

Kimberly A Miller, PhD
323-865-0674
kim.miller@med.usc.edu

Detailed Description

PRIMARY OBJECTIVES: I. Characterize the trajectories of social health in young adult (YA) cancer patients. II. Investigate the longitudinal associations between social health and activity behaviors in YA cancer patients. III. Explore the effects of sociodemographic and clinical characteristics on the relationship between social health, activity behaviors, and quality of life. OUTLINE: Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.